Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn’s Disease
Stephan R. Targan, Brian G. Feagan, Séverine Vermeire, et al.
The American Journal of Gastroenterology (2016) Vol. 111, Iss. 11, pp. 1599-1607
Closed Access | Times Cited: 328

Showing 1-25 of 328 citing articles:

The IL-17 Family of Cytokines in Health and Disease
Mandy J. McGeachy, J. Daniel, Sarah L. Gaffen
Immunity (2019) Vol. 50, Iss. 4, pp. 892-906
Open Access | Times Cited: 1096
IL-17 Signaling: The Yin and the Yang
Nilesh Amatya, Abhishek V. Garg, Sarah L. Gaffen
Trends in Immunology (2017) Vol. 38, Iss. 5, pp. 310-322
Open Access | Times Cited: 640
Cytokine Networks in the Pathophysiology of Inflammatory Bowel Disease
Matthias Friedrich, Mathilde Pohin, Fiona Powrie
Immunity (2019) Vol. 50, Iss. 4, pp. 992-1006
Open Access | Times Cited: 591
The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis
Andrew Blauvelt, Andrea Chiricozzi
Clinical Reviews in Allergy & Immunology (2018) Vol. 55, Iss. 3, pp. 379-390
Open Access | Times Cited: 590
IL-17 and IL-17-producing cells in protection versus pathology
Kingston H. G. Mills
Nature reviews. Immunology (2022) Vol. 23, Iss. 1, pp. 38-54
Open Access | Times Cited: 533
Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis
Jason E. Hawkes, Bernice Y. Yan, Tom C. Chan, et al.
The Journal of Immunology (2018) Vol. 201, Iss. 6, pp. 1605-1613
Open Access | Times Cited: 480
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
Kristian Reich, Kim Papp, Andrew Blauvelt, et al.
The Lancet (2017) Vol. 390, Iss. 10091, pp. 276-288
Closed Access | Times Cited: 477
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study
Brian G. Feagan, William J. Sandborn, Geert R. DʼHaens, et al.
The Lancet (2017) Vol. 389, Iss. 10080, pp. 1699-1709
Open Access | Times Cited: 401
IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting
Alexander R. Moschen, Herbert Tilg, Tim Raine
Nature Reviews Gastroenterology & Hepatology (2018) Vol. 16, Iss. 3, pp. 185-196
Closed Access | Times Cited: 393
Fibroblasts as immune regulators in infection, inflammation and cancer
Sarah Davidson, Mark Coles, Tom Thomas, et al.
Nature reviews. Immunology (2021) Vol. 21, Iss. 11, pp. 704-717
Open Access | Times Cited: 380
Serum Amyloid A Proteins Induce Pathogenic Th17 Cells and Promote Inflammatory Disease
June‐Yong Lee, Jason A. Hall, Lina Kroehling, et al.
Cell (2019) Vol. 180, Iss. 1, pp. 79-91.e16
Open Access | Times Cited: 351
Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis?
Kenneth F. Baker, John D. Isaacs
Annals of the Rheumatic Diseases (2017) Vol. 77, Iss. 2, pp. 175-187
Closed Access | Times Cited: 337
Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies
José María García Ruiz de Morales, L. Puig, E. Daudén, et al.
Autoimmunity Reviews (2019) Vol. 19, Iss. 1, pp. 102429-102429
Open Access | Times Cited: 275
Th17 plasticity and its relevance to inflammatory bowel disease
Aito Ueno, Louisa Jeffery, Taku Kobayashi, et al.
Journal of Autoimmunity (2017) Vol. 87, pp. 38-49
Closed Access | Times Cited: 241
Effector T Helper Cell Subsets in Inflammatory Bowel Diseases
Tanbeena Imam, Sungtae Park, Mark H. Kaplan, et al.
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 231
Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation
Sophie Glatt, Dominique Baeten, Terry Baker, et al.
Annals of the Rheumatic Diseases (2017) Vol. 77, Iss. 4, pp. 523-532
Open Access | Times Cited: 219
The role of interleukin-17 in tumor development and progression
Junjie Zhao, Xing Chen, Tomasz Herjan, et al.
The Journal of Experimental Medicine (2019) Vol. 217, Iss. 1
Open Access | Times Cited: 189
Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis
William J. Sandborn, Marc Ferrante, Bal Raj Bhandari, et al.
Gastroenterology (2019) Vol. 158, Iss. 3, pp. 537-549.e10
Open Access | Times Cited: 183
Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review
Masahiro Kamata, Yayoi Tada
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 5, pp. 1690-1690
Open Access | Times Cited: 180
Paradoxical gastrointestinal effects of interleukin-17 blockers
Marine Fauny, David Moulin, Ferdinando D’Amico, et al.
Annals of the Rheumatic Diseases (2020) Vol. 79, Iss. 9, pp. 1132-1138
Open Access | Times Cited: 180
Role of IL‐25, IL‐33, and TSLP in triggering united airway diseases toward type 2 inflammation
Haiyu Hong, Shumin Liao, Fenghong Chen, et al.
Allergy (2020) Vol. 75, Iss. 11, pp. 2794-2804
Open Access | Times Cited: 179
Interleukin-17 in Chronic Inflammatory Neurological Diseases
Jelena Milovanović, Aleksandar Arsenijević, Bojana Stojanović, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 169
Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials
Stefan Schreiber, Jean‐Frédéric Colombel, Brian G. Feagan, et al.
Annals of the Rheumatic Diseases (2019) Vol. 78, Iss. 4, pp. 473-479
Open Access | Times Cited: 167
Somatic Evolution in Non-neoplastic IBD-Affected Colon
Sigurgeir Ólafsson, Rebecca E. McIntyre, Tim H. H. Coorens, et al.
Cell (2020) Vol. 182, Iss. 3, pp. 672-684.e11
Open Access | Times Cited: 164
The IL-17 family in diseases: from bench to bedside
Longjie Huangfu, Ruiying Li, Yamei Huang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 148
Page 1 - Next Page

Scroll to top